171 related articles for article (PubMed ID: 33312060)
21. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer.
Kruger S; Legenstein ML; Rösgen V; Haas M; Modest DP; Westphalen CB; Ormanns S; Kirchner T; Heinemann V; Holdenrieder S; Boeck S
Oncoimmunology; 2017; 6(5):e1310358. PubMed ID: 28638732
[TBL] [Abstract][Full Text] [Related]
23. Soluble Programmed Cell Death Protein 1 and Its Ligand: Potential Biomarkers to Predict Acute Kidney Injury After Surgery in Critically Ill Patients.
Wang J; Zheng X; Jiang Y; Jia H; Shi X; Han Y; Li Q; Li W
J Inflamm Res; 2022; 15():1995-2008. PubMed ID: 35356070
[TBL] [Abstract][Full Text] [Related]
24. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H; Sunakawa Y; Inoue E; Matoba R; Noda K; Sato T; Suminaka C; Yamaki M; Sakamoto Y; Kawabata R; Ishiguro A; Akamaru Y; Kito Y; Yabusaki H; Matsuyama J; Takahashi M; Makiyama A; Hayashi H; Chamoto K; Honjo T; Nakagawa K; Ichikawa W; Fujii M
Eur J Cancer; 2023 May; 184():10-20. PubMed ID: 36889037
[TBL] [Abstract][Full Text] [Related]
25. The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer.
Shao W; Xu Y; Lin S; Gao J; Gao J; Wang H
Front Oncol; 2022; 12():988567. PubMed ID: 36052227
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer.
Molga-Magusiak M; Rzepakowska A; Żurek M; Kotuła I; Demkow U; Niemczyk K
Braz J Otorhinolaryngol; 2023; 89(3):417-424. PubMed ID: 36868994
[TBL] [Abstract][Full Text] [Related]
27. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
Cheng CL; Yao CY; Huang PH; Yu CW; Fang WQ; Chuang WH; Wu SJ; Lin YJ; Hung YC; Tsai CH; Yu SC; Chou WC; Tien HF
Br J Haematol; 2023 Apr; 201(1):75-85. PubMed ID: 36480431
[TBL] [Abstract][Full Text] [Related]
29. Serum sPD-L1, Upregulated in Sepsis, May Reflect Disease Severity and Clinical Outcomes in Septic Patients.
Liu M; Zhang X; Chen H; Wang G; Zhang J; Dong P; Liu Y; An S; Wang L
Scand J Immunol; 2017 Jan; 85(1):66-72. PubMed ID: 27864994
[TBL] [Abstract][Full Text] [Related]
30. Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients.
Nasiri Kalmarzi R; Fattahi N; Kaviani Z; Ataee P; Mansouri M; Moradi G; Yousefzade A; Abbassi JM
Allergol Int; 2017 Apr; 66(2):326-331. PubMed ID: 27617656
[TBL] [Abstract][Full Text] [Related]
31. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
Shen H; Ji Y; Zhou D; Zhang Y; Wang W; Sun J; Zhang W
Hematology; 2019 Dec; 24(1):392-398. PubMed ID: 30890046
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.
Takahashi N; Iwasa S; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita NT; Kato K; Hamaguchi T; Yamada Y
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1727-38. PubMed ID: 27256004
[TBL] [Abstract][Full Text] [Related]
33. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].
Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ
Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155
[No Abstract] [Full Text] [Related]
34. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity.
Du Y; Nie L; Xu L; Wu X; Zhang S; Xue J
Scand J Immunol; 2020 Jul; 92(1):e12884. PubMed ID: 32243638
[TBL] [Abstract][Full Text] [Related]
36. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer.
Aghajani MJ; Roberts TL; Yang T; McCafferty CE; Caixeiro NJ; DeSouza P; Niles N
Endocr Connect; 2019 Jul; 8(7):1040-1051. PubMed ID: 31252406
[TBL] [Abstract][Full Text] [Related]
37. Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis.
Chen H; Peng Q; Yang H; Yin L; Shi J; Zhang Y; Wang G
J Rheumatol; 2018 Jun; 45(6):835-840. PubMed ID: 29419471
[TBL] [Abstract][Full Text] [Related]
38. The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients.
Ancın B; Özercan MM; Yılmaz YM; Uysal S; Kumbasar U; Sarıbaş Z; Dikmen E; Doğan R; Demircin M
Turk J Med Sci; 2022 Aug; 52(4):1050-1057. PubMed ID: 36326416
[TBL] [Abstract][Full Text] [Related]
39. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.
Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Terai S
Int J Med Sci; 2017; 14(5):403-411. PubMed ID: 28539815
[No Abstract] [Full Text] [Related]
40. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
